Motilal Oswal

FINANCIAL SERVICES

Eris Lifesciences

Estimate change	 CN
TP change	
Rating change	 – Re

Bloomberg	ERIS IN
Equity Shares (m)	136
M.Cap.(INRb)/(USDb)	170.2 / 2
52-Week Range (INR)	1594 / 809
1, 6, 12 Rel. Per (%)	-1/17/33
12M Avg Val (INR M)	243

Financials & valuations (INR b)

Y/E MARCH	2025E	2026E	2027E		
Sales	29.7	33.9	39.2		
EBITDA	10.5	11.9	14.1		
Adj. PAT	3.8	5.5	7.6		
EBIT Margin (%)	24.3	25.6	27.7		
Cons. Adj. EPS (INR)	27.4	40.1	55.2		
EPS Gr. (%)	-6.2	46.2	37.6		
BV/Sh. (INR)	210.0	244.6	294.4		
Ratios					
Net D:E	0.7	0.5	0.2		
RoE (%)	13.8	17.6	20.5		
RoCE (%)	11.0	13.5	16.7		
Payout (%)	20.0	13.7	10.0		
Valuations					
P/E (x)	44.7	30.6	22.2		
EV/EBITDA (x)	18.1	15.5	12.6		
Div. Yield (%)	0.4	0.4	0.4		
FCF Yield (%)	4.8	4.3	4.8		
EV/Sales (x)	6.4	5.4	4.5		

Shareholding pattern (%)

54.9	54.9	54.9
18.1	18.7	14.6
8.4	8.0	13.1
18.7	18.5	17.4
	18.1 8.4	18.1 18.7 8.4 8.0

FII includes depository receipts

CMP: INR1,231

TP: INR1,270 (+3%)

Neutral

Recovery in base business, acquisitions drive operational performance

Preparing to benefit from GLP1 opportunity

- Eris Lifescience's (ERIS) 3QFY25 performance came in below our estimates. Lower-than-expected revenue growth led to lower operating leverage, which affected the overall performance. The base business witnessed some recovery in growth owing to new launches and price hikes.
- We reduce our FY25 EPS estimate by 4% (factoring in lower sales from biologics business) and largely maintain our estimates for FY26/FY27. We value ERIS at 25x 12M forward earnings to arrive at a TP of INR1,270.
- ERIS is building the GLP1 franchise by ensuring the sourcing of API for synthetic peptide and subsequently conducting clinical trials/enhancing manufacturing capacity for recombinant semaglutide. It continues to launch combination products in the SGLT2 space. Considering this and a reduction in financial leverage, we estimate a CAGR of 16%/42% in EBITDA/earnings over FY25-27. However, the current valuation leaves limited upside. Reiterate Neutral.

Business mix impact offset partly by better operating leverage (YoY)

- 3QFY25 revenue grew 49.6% YoY to INR7.3b (our est. INR7.7b). After the addition of Biocon II business, total domestic business grew 35% YoY to INR6.3b. Organic base domestic business grew 12% YoY to INR5.3b on the back of new product launches and price increases.
- Gross margin contracted 560bp YoY to 75.7% due to higher raw material costs and a change in the business mix.
- EBITDA margin contracted 170bp YoY to 34.4% (our est. 35.3%), owing to a change in the business mix, offset by lower employee expenses/other expenses (-300bp/-130bp as % of sales).
- EBITDA, however, increased by 43% YoY to INR2.5b (our est. INR2.7b).
 - Adj. PAT declined 18.6% YoY to INR836m (our est. INR1b), due to higher interest (up 2.1x YoY) and depreciation (up 77% YoY).
- For 9MFY25, revenue/EBITDA grew 50.1%/45.3%, whereas PAT declined 19.5% YoY.

Highlights from the management commentary

- ERIS expects net debt at INR21b as of FY25 end vs. earlier guidance of INR26b.
- ERIS maintains its FY25 revenue/EBIDTA margin guidance of INR30b/35%.
- ERIS aims to achieve 22% ROCE in FY25 (vs. 19% in FY24) through base business growth, operating leverage, and the addition of newer growth levers.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Akash Manish Dobhada (Akash.Dobhada@MotilalOswal.com) | Viraj Shah (Viraj.Shah@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.


Consolidated - Quarterly Farning

Consolidated - Quarterly Earning (INR m)												
Y/E March		FY	24			FY2	5E		FY24	FY25E	Estimate	Var %
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE			3QE	
Gross Sales	4,666	5,053	4,863	5,509	7,197	7,412	7,275	7,863	20,091	29,747	7,732	-5.9
YoY Change (%)	17.1	9.7	14.9	36.8	54.2	46.7	49.6	42.7	19.2	48.1	59.0	
Total Expenditure	2,969	3,242	3,108	3,811	4,697	4,767	4,771	5,041	13,129	19,276	5,003	
EBITDA	1,697	1,811	1,755	1,698	2,500	2,645	2,503	2,823	6,962	10,471	2,729	-8.3
Margins (%)	36.4	35.8	36.1	30.8	34.7	35.7	34.4	35.9	34.7	35.2	35.3	
Depreciation	409	421	457	539	759	805	812	852	1,830	3,228	810	
Interest	174	163	181	330	604	595	572	579	848	2,349	610	
Other Income	10	35	42	151	16	46	42	193	238	297	65	
PBT before EO expense	1,125	1,262	1,159	980	1,153	1,291	1,162	1,586	4,522	5,192	1,374	-15.5
Extra-Ord expense	0	0	0	214	0	0	0	0	214	0	0	
РВТ	1,125	1,262	1,159	766	1,153	1,291	1,162	1,586	4,308	5,192	1,374	
Тах	188	39	144	-30	259	328	292	393	342	1,272	330	
Rate (%)	16.7	3.1	12.4	-3.9	22.5	25.4	25.2	24.8	7.9	24.5	24.0	
MI & Profit/Loss of Asso. Cos.	12	11	13	-87	62	48	33	4	-51	147	37.0	
Reported PAT	948	1,234	1,027	710	832	916	836	1,189	3,916	3,773	1,008	-17.0
Adj PAT	948	1,234	1,027	815	832	916	836	1,189	4,021	3,773	1,008	-17.0
YoY Change (%)	0.3	2.3	1.2	24.6	-12.3	-25.8	-18.6	45.8	5.2	-6.2	-1.9	
Margins (%)	20.3	24.4	21.1	14.8	11.6	12.4	11.5	15.1	20.0	12.7	13.0	

CONFERENCI CALL

Highlights from the management interaction

- ERIS expects its Bhopal facility to be operational from FY26 onward. Insourcing of vials will give benefits from 1QFY26. Subsequently, insourcing of cartridges would also drive margin expansion. ERIS targets EU-GMP and ROW market approvals.
- Brazil ANVISA inspection is expected in May'25 at its AMD unit.
- ERIS is launching new products (Dapagliflozin combination, sitaglitpin combination) in 4QFY25.
- ERIS has already launched certain Dapagliflozin combinations in 3QFY25.
- Liraglutide sales reached INR10m per month after its launch in Sep'24.
- ERIS would be conducting human trials related to Levim. The commercial launch is expected by CY26 end.



Source: MOFSL, Company, Bloomberg

Source: MOFSL, Company, Bloomberg

Acquisitions, new launches to drive growth in medium term

Gearing up to leverage the GLP-1 market opportunities

- As of Dec'24, Eris has 6% market share in overall diabetes therapy. Eris is the largest Indian company in the insulin market with a 10% market share.
- After the acquisition of Levim and Chemman labs, Eris received capabilities to develop analogies, GLP-1 agonists, rDNA and other monoclonal anti-bodies, enhancing its presence in niche and complex segments.
- Eris' first GLP-1 product, Liraglutide, launched in Sep'24 ramped up to monthly sales of INR10m.
- Moreover, Eris launched three first-in-market Dapagliflozin combinations in 3QFY25 – a differentiated play in the fast-growing SGLT2 space.
- Eris entered into a strategic partnership for the launch of Semaglutide, where Eris will be among the few players to launch it first in India.
- Further, Eris is preparing its Bhopal facility for "form-fill-finish" recombinant Sema for FY26.
- Eris has a strong pipeline opportunity in Gliclazide + combinations and Empagliflozin + combinations in 4QFY25.


Working on niche products to drive growth over medium term

- In 9MFY25, total domestic formulation revenue grew 35% YoY to INR19b, driven by new product launches and price increases. Further, the integration of the acquired portfolio is also driving growth.
- Including the Biologic 1 acquisition, organic domestic formulation business grew 9% YoY to INR15b with EBITDA margin of 40%, while revenue from Biologic 2 business stood at INR3b in 9MFY25.
- ERIS plans to launch multiple new products with several first-to-market in FY26.
- We expect ERIS to outperform the industry over the medium term, as it has established its presence in the cardiac/antidiabetic segments. Additionally, the new product pipeline and patent expiries in its focus therapies provide growth visibility. We expect ERIS to post a CAGR of 9.6% in overall sales over FY25-27.

Valuation and view


- We reduce our FY25 EPS estimate by 4% (factoring lower sales from biologics business) and largely maintain our estimates for FY26/FY27. We value ERIS at 25x 12M forward earnings to arrive at a TP of INR1,270.
- ERIS is building the GLP1 franchise by ensuring the sourcing of API for synthetic peptide and subsequently conducting clinical trials/enhancing manufacturing capacity for recombinant semaglutide. It continues to launch combination products in SGLT2 space. Considering this and a reduction in financial leverage, we estimate a CAGR of 16%/42% in EBITDA/earnings over FY25-27. However, the current valuation leaves limited upside. Maintain Neutral.


Story in Charts













Source: MOFSL, Company




Source: MOFSL, Company

Exhibit 6: EBITDA margin to expand 130bp over FY24-27E



Source: MOFSL, Company

Exhibit 8: RoE to expand to 21% by 27E



Financial and valuations

Consolidated - Income Statement Y/E March	FY21	FY22	FY23	FY24	FY25E	FY26E	(INR m) FY27E
Total Income from Operations	12,119	13,470	16,851	20,091	29,747	33,918	39,168
Change (%)	12.8	11.2	25.1	19.2	48.1	14.0	15.5
Total Expenditure	7.813	8,621	11,484	13,129	19,276	22,013	25,067
EBITDA	4,306	4,850	5,368	6,962	10,471	11,905	14,100
Margin (%)	35.5	36.0	31.9	34.7	35.2	35.1	36.0
Depreciation	430	647	1,171	1,830	3,228	3,236	3,233
EBIT	3,876	4,203	4,197	5,132	7,243	8,669	10,867
Int. and Finance Charges	18	41	262	848	2,349	1,517	977
Other Income	87	261	112	238	297	339	392
PBT bef. EO Exp.	3,945	4,422	4,046	4,522	5,192	7,491	10,282
EO Items	0	0	0	-214	0	0	Ċ
PBT after EO Exp.	3,945	4,422	4,046	4,308	5,192	7,491	10,282
Total Tax	394	364	305	342	1,272	1,820	2,529
Tax Rate (%)	10.0	8.2	7.5	7.9	24.5	24.3	24.6
Minority Interest	0	0	80	-51	147	154	162
Reported PAT	3,551	4,058	3,822	3,916	3,773	5,517	7,591
Adjusted PAT	3,551	4,058	3,822	4,021	3,773	5,517	7,591
Change (%)	19.9	14.3	-5.8	5.2	-6.2	46.2	37.6
Margin (%)	29.3	30.1	22.7	20.0	12.7	16.3	19.4
Consolidated - Balance Sheet							(INR m)
Y/E March	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
Equity Share Capital	136	136	136	136	136	136	136
Total Reserves	15,628	18,947	21,824	25,725	28,742	33,503	40,337
Net Worth	15,764	19,083	21,960	25,861	28,878	33,639	40,473
Minority Interest	0	-1	247	6,359	6,359	6,359	6,359
Total Loans	0	450	8,300	27,353	21,353	16,853	10,853
Deferred Tax Liabilities	-1,511	-1,970	-163	2,359	2,359	2,359	2,359
Capital Employed	14,253	17,562	30,344	61,931	58,948	59,209	60,044
Gross Block	1,757	2,506	4,634	6,726	6,943	7,088	7,221
Less: Accum. Deprn.	978	1,294	1,594	2,164	2,847	3,408	3,966
Net Fixed Assets	779	1,212	3,040	4,562	4,096	3,679	3,254
Gross intangible asset	7,366	7,439	20,546	32,621	32,621	32,621	32,621
Accumulated amortization	541	873	1,744	3,004	5,548	8,223	10,898
Net intangible asset	6,825	6,566	18,803	29,617	27,073	24,398	21,723
Goodwill on Consolidation	935	935	3,318	8,612	8,612	8,612	8,612

16

2,940

4,847

1,405

2,114

2,088

1,026

474

588

2,759

14,253

945

383

270

5,204

6,103

1,179

1,610

2,791

2,728

1,178

839

712

3,375

17,562

523

217

367

8,189

1,314

2,927

3,387

3,590

1,248

1,207

1,136

4,599

30,344

560

197

155

24,276

1,890

4,220

17,224

5,487

2,683

1,656

1,148

18,789

61,931

942

99

155

27,005

2,775

6,248

17,848

8,092

3,940

2,453

1,699

18,913

58,948

134

85

155

31,514

3,169

7,124

20,351

9,233

4,499

2,797

1,938

22,280

59,209

870

82

155

36,808 3,609

8,227

1,472

23,501

10,591

5,124

3,230

2,237

26,217

60,044

Capital WIP

Inventory

Provisions

Total Investments

Account Receivables

Loans and Advances

Account Payables

Net Current Assets

Appl. of Funds

Curr. Liability & Prov.

Other Current Liabilities

Cash and Bank Balance

Curr. Assets, Loans&Adv.

Financial and valuations

Ratios Y/E March	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
			_				
EPS	25.8	29.5	27.8	29.2	27.4	40.1	55.2
Cash EPS	29.0	34.2	36.3	42.6	50.9	63.7	78.7
BV/Share	114.6	138.8	159.7	188.1	210.0	244.6	294.4
DPS	5.5	5.5	5.5	5.5	5.5	5.5	5.5
Payout (%)	21.3	18.6	19.8	19.3	20.0	13.7	10.0
Valuation (x)							
P/E	47.5	41.5	44.1	41.9	44.7	30.6	22.2
Cash P/E	42.3	35.8	33.8	28.8	24.1	19.3	15.6
P/BV	10.7	8.8	7.7	6.5	5.8	5.0	4.2
EV/Sales	13.9	12.5	10.5	9.7	6.4	5.4	4.5
EV/EBITDA	39.1	34.7	32.8	28.0	18.1	15.5	12.6
Dividend Yield (%)	0.4	0.4	0.4	0.4	0.4	0.4	0.4
FCF per share	25.4	18.8	-40.0	-15.3	59.2	53.3	58.9
Return Ratios (%)							
RoE	24.7	23.3	18.6	16.8	13.8	17.6	20.5
RoCE	24.8	23.2	16.0	11.8	11.0	13.5	16.7
RoIC	32.9	34.3	19.0	10.5	9.2	11.3	14.1
Working Capital Ratios							
Inventory (Days)	28	32	28	34	34	34	34
Debtor (Days)	42	44	63	77	77	77	77
Creditor (Days)	31	32	27	49	48	48	48
Leverage Ratio (x)							
Net Debt/Equity	-0.2	-0.3	0.3	1.0	0.7	0.5	0.2
Consolidated - Cash Flow Statement							
Y/E March	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E
OP/(Loss) before Tax	3,945	4,422	4,046	4,312	5,192	7,491	10,282
Depreciation	430	647	1,171	1,826	3,228	3,236	3,233
Interest & Finance Charges	-5	41	262	848	2,051	1,178	585
Direct Taxes Paid	-685	-833	-772	-1,008	-1,272	-1,820	-2,529
(Inc)/Dec in WC	53	-299	-1,755	-1,008	-1,272	-2,631	-3,335
CF from Operations	3,738	-299 3,979	2,952	-987 4,992	-954 8,265	-2,051 7,453	-3,335 8,235
· · · · · · · · · · · · · · · · · · ·							
Others	16	-196	-34	-131	0	0	0

Inc/Dec of Cash	-291	140	-23	384	-809	736	602
Opening Balance	673	384	523	560	944	134	870
Others	0	0	60	0	0		
Closing Balance	383	523	560	944	134	870	1,472

3,783

-1,203

2,580

-1,881

-**3,196**

-112

0

450

-39

-816

-42

-447

2,917

-8,413

-5,495

4,904

-6,313

-9,821

7,850

-234

-999

264

6,880

0

4,860

-6,960

-2,100

-11,656

-18,545

14,628

-773

168

14,069

0

70

45

3,754

-257

3,497

-2,946

-3,220

-17

0

-59

-18

-747

-824

0

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

CF from Operating incl EO

(Pur)/Sale of Investments

CF from Investments

CF from Fin. Activity

(Inc)/Dec in FA

Free Cash Flow

Issue of Shares

Interest Paid

Dividend Paid

Inc/(Dec) in Debt

Others

Others

8,235

-130

8,105

0

392

262

-6,000

-977

-756

-162

-7,895

0

7,453

-130

7,323

0

339

209

-4,500

-1,517

-756

-154

-6,927

0

8,265

-120

8,145

0

0

297

177

-6,000

-2,349

-756

-147

-9,252

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various fin ancial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at ereports.motilaloswal.com/Dormant/documents/List%20 20Associate%20companies.pd

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at alaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong. For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes. Nature of Financial interest is holding equity shares or derivatives of the subject company

2. Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No

- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months. 3.
- MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report. 4
- MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies). 5
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months. 6.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months. 7.

MOTILAL OSWAL

- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- 9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- 10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability/arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No: 022-40548085.

Grie	var	ICE	e R	edr	es
-			_		

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.